- Home
- EXEL vs CLMT Comparison
EXEL vs CLMT Comparison
Compare EXEL & CLMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- CLMT
- Stock Information
- Founded
- EXEL 1994
- CLMT 1916
- Country
- EXEL United States
- CLMT United States
- Employees
- EXEL N/A
- CLMT N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- CLMT Oil & Gas Production
- Sector
- EXEL Health Care
- CLMT Energy
- Exchange
- EXEL Nasdaq
- CLMT Nasdaq
- Market Cap
- EXEL 9.8B
- CLMT N/A
- IPO Year
- EXEL 2000
- CLMT 2006
- Fundamental
- Price
- EXEL $36.17
- CLMT $12.32
- Analyst Decision
- EXEL Buy
- CLMT Strong Buy
- Analyst Count
- EXEL 18
- CLMT 5
- Target Price
- EXEL $37.59
- CLMT $21.60
- AVG Volume (30 Days)
- EXEL 2.3M
- CLMT 975.6K
- Earning Date
- EXEL 05-13-2025
- CLMT 05-09-2025
- Dividend Yield
- EXEL N/A
- CLMT N/A
- EPS Growth
- EXEL 170.77
- CLMT N/A
- EPS
- EXEL 1.76
- CLMT N/A
- Revenue
- EXEL $2,168,701,000.00
- CLMT $4,177,500,000.00
- Revenue This Year
- EXEL $5.78
- CLMT N/A
- Revenue Next Year
- EXEL $10.94
- CLMT $1.44
- P/E Ratio
- EXEL $20.55
- CLMT N/A
- Revenue Growth
- EXEL 18.50
- CLMT 0.68
- 52 Week Low
- EXEL $20.14
- CLMT $7.68
- 52 Week High
- EXEL $40.26
- CLMT $25.29
- Technical
- Relative Strength Index (RSI)
- EXEL 43.89
- CLMT 61.54
- Support Level
- EXEL $34.90
- CLMT $10.14
- Resistance Level
- EXEL $40.26
- CLMT $11.34
- Average True Range (ATR)
- EXEL 1.21
- CLMT 0.58
- MACD
- EXEL -0.19
- CLMT 0.32
- Stochastic Oscillator
- EXEL 23.69
- CLMT 95.03
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.